Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease

被引:97
作者
Mocci, Giammarco [1 ]
Marzo, Manuela [2 ]
Papa, Alfredo [2 ]
Armuzzi, Alessandro [2 ]
Guidi, Luisa [2 ]
机构
[1] Brotzu Hosp, Gastroenterol Unit, I-09121 Cagliari, Italy
[2] Univ Cattolica Sacro Cuore, Internal Med & Gastroenterol Unit, Rome, Italy
关键词
Anti-TNF; IBD; Skin manifestations; NECROSIS FACTOR THERAPY; FACTOR-ALPHA THERAPY; DRUG-INDUCED LUPUS; ADALIMUMAB-INDUCED PSORIASIS; NONMELANOMA SKIN CANCERS; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; INFUSION REACTIONS; AUTOIMMUNE-DISEASES; SERIOUS INFECTIONS;
D O I
10.1016/j.crohns.2013.01.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The clinical introduction of tumour necrosis factor (TNF) inhibitors has deeply changed the treatment of inflammatory bowel diseases (IBD). It has demonstrated impressive efficacy as compared to alternative treatments, allowing for the chance to achieve near-remission and long-term improvement in function and quality of life and to alter the natural history of Crohn's disease (CD) and ulcerative colitis (UC). As a consequence of longer follow-up periods the number of side effects which may be attributed to treatment with biologics is growing significantly. Cutaneous reactions are among the most common adverse reactions. These complications include injection site reactions, cutaneous infections, immune-mediated complications such as psoriasis and lupus-like syndrome and rarely skin cancers. We review the recent literature and draw attention to dermatological side effects of anti-TNF therapy of inflammatory bowel disease. (C) 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:769 / 779
页数:11
相关论文
共 128 条
  • [1] Adams David R, 2006, J Drugs Dermatol, V5, P178
  • [2] Another paradox in Crohn's disease:: New onset of psoriasis in a patient receiving tumor necrosis factor-α antagonist
    Angelucci, Erika
    Cocco, Andrea
    Viscido, Angelo
    Vernia, Piero
    Caprilli, Renzo
    [J]. INFLAMMATORY BOWEL DISEASES, 2007, 13 (08) : 1059 - 1061
  • [3] Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-α therapy
    Antoniou, Christina
    Kosmadaki, Maria G.
    Stratigos, Alexandros J.
    Katsambas, Andreas D.
    [J]. DERMATOLOGY, 2008, 216 (04) : 364 - 365
  • [4] Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
    Askling, Johan
    Fored, C. Michael
    Brandt, Lena
    Baecklund, Eva
    Bertilsson, Lennart
    Feltelius, Nils
    Coster, Lars
    Geborek, Pierre
    Jacobsson, Lennart T.
    Lindblad, Staffan
    Lysholm, Jorgen
    Rantapaa-Dahlqvist, Solbritt
    Saxne, Tore
    van Vollenhoven, Ronald F.
    Klareskog, Lars
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) : 1339 - 1344
  • [5] Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
    Askling, Johan
    Fahrbach, Kyle
    Nordstrom, Beth
    Ross, Susan
    Schmid, Christopher H.
    Symmons, Deborah
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) : 119 - 130
  • [6] Autoimmunity and anti-TNF-α agents
    Atzeni, F
    Turiel, M
    Capsoni, F
    Doria, A
    Meroni, P
    Sarzi-Puttini, P
    [J]. AUTOIMMUNE DISEASES AND TREATMENT: ORGAN-SPECIFIC AND SYSTEMIC DISORDERS, 2005, 1051 : 559 - 569
  • [7] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [8] Frequency, Phenotype, Outcome, and Therapeutic Impact of Skin Reactions Following Initiation of Adalimumab Therapy: Experience from a Consecutive Cohort of Inflammatory Bowel Disease Patients
    Baumgart, Daniel C.
    Grittner, Ulrike
    Steingraeber, Andrea
    Azzaro, Marina
    Philipp, Sandra
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 (12) : 2512 - 2520
  • [9] Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis
    Bernatsky, S.
    Hudson, M.
    Suissa, S.
    [J]. RHEUMATOLOGY, 2007, 46 (07) : 1157 - 1160
  • [10] Skin reaction to adalimumab
    Beuthien, W
    Mellinghoff, HU
    von Kempis, J
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (05): : 1690 - 1692